Laure Gossec to Middle Aged
This is a "connection" page, showing publications Laure Gossec has written about Middle Aged.
Connection Strength
0.174
-
Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries. Arthritis Care Res (Hoboken). 2020 12; 72(12):1772-1779.
Score: 0.015
-
Criteria for inclusion in programs of functional restoration for chronic low back pain: Pragmatic Study. Ann Phys Rehabil Med. 2020 May; 63(3):189-194.
Score: 0.013
-
Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale. J Rheumatol. 2019 10; 46(10):1259-1267.
Score: 0.013
-
Development and application of a questionnaire to assess patient beliefs in rheumatoid arthritis and axial spondyloarthritis. Clin Rheumatol. 2018 Oct; 37(10):2649-2657.
Score: 0.012
-
Fears and beliefs of people living with rheumatoid arthritis: a systematic literature review. Adv Rheumatol. 2018 May 24; 58(1):1.
Score: 0.012
-
Phrasing of the patient global assessment in the rheumatoid arthritis ACR/EULAR remission criteria: an analysis of 967 patients from two databases of early and established rheumatoid arthritis patients. Clin Rheumatol. 2018 Jun; 37(6):1503-1510.
Score: 0.012
-
The revised Bristol Rheumatoid Arthritis Fatigue measures and the Rheumatoid Arthritis Impact of Disease scale: validation in six countries. Rheumatology (Oxford). 2018 02 01; 57(2):300-308.
Score: 0.012
-
Development and psychometric validation of a patient-reported outcome measure to assess fears in rheumatoid arthritis and axial spondyloarthritis: the Fear Assessment in Inflammatory Rheumatic diseases (FAIR) questionnaire. Ann Rheum Dis. 2018 02; 77(2):258-263.
Score: 0.012
-
Primary inefficacy of TNF inhibitors in patients with axial spondyloarthritis: a long-term follow-up of 25 patients. Rheumatology (Oxford). 2017 06 01; 56(6):896-900.
Score: 0.011
-
Psychometric properties of sleep and coping numeric rating scales in rheumatoid arthritis: a subanalysis of an etanercept trial. Clin Exp Rheumatol. 2017 Sep-Oct; 35(5):786-790.
Score: 0.011
-
Patient-reported outcomes in Asia: evaluation of the properties of the Rheumatoid Arthritis Impact of Disease (RAID) score in multiethnic Asian patients with rheumatoid arthritis. Clin Rheumatol. 2017 May; 36(5):1149-1154.
Score: 0.011
-
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021 09; 80(9):1137-1146.
Score: 0.004
-
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021 07; 80(7):930-942.
Score: 0.004
-
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020 07; 79(7):859-866.
Score: 0.004
-
Psychometric properties and cross-language equivalence of the revised Bristol Rheumatoid Arthritis Fatigue and the Rheumatoid Arthritis Impact of Disease scales in rheumatoid arthritis. Qual Life Res. 2019 Sep; 28(9):2543-2552.
Score: 0.003
-
The effects of cultural background on patient-perceived impact of psoriatic arthritis - a qualitative study conducted in Brazil and France. Adv Rheumatol. 2018 Oct 22; 58(1):33.
Score: 0.003
-
The Portuguese Rheumatoid Arthritis Impact of Disease (RAID) score and its measurement equivalence in three countries: validation study using Rasch Models. Qual Life Res. 2018 Nov; 27(11):2909-2921.
Score: 0.003
-
Frequency of tumour necrosis factor alpha receptor superfamily 1A multiple sclerosis-associated variants in patients with rheumatoid arthritis with anti-tumour necrosis factor therapy-related demyelinating complications. Ann Rheum Dis. 2018 12; 77(12):1835-1836.
Score: 0.003
-
Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis. Arthritis Res Ther. 2018 06 19; 20(1):129.
Score: 0.003
-
Suppressing Inflammation in Rheumatoid Arthritis: Does Patient Global Assessment Blur the Target? A Practice-Based Call for a Paradigm Change. Arthritis Care Res (Hoboken). 2018 03; 70(3):369-378.
Score: 0.003
-
Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers' effectiveness in axial spondyloarthritis: results of a prospective, multicentre study. Ann Rheum Dis. 2018 04; 77(4):533-540.
Score: 0.003
-
An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS. Ann Rheum Dis. 2018 Jan; 77(1):124-127.
Score: 0.003
-
Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients. Rheumatology (Oxford). 2017 09 01; 56(9):1573-1578.
Score: 0.003